<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04293289</url>
  </required_header>
  <id_info>
    <org_study_id>CNCT-001/SPM-011-JAM001</org_study_id>
    <nct_id>NCT04293289</nct_id>
  </id_info>
  <brief_title>Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma</brief_title>
  <official_title>Phase 1 Clinical Trial of Boron Neutron Capture Therapy (BNCT) Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Intelligence Care Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stella Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Intelligence Care Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among skin malignancies, patients with malignant melanoma or angiosarcoma are treated with
      BNCT using CICS-1 and SPM-011 (borofalan (10B)). Through this trial, safety and appropriate
      treatment dose will be determined.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency of DLT(Dose Limiting Toxicity) occurence (Safety)</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluate the safety at each dose level by the frequency of DLT occurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events and failures</measure>
    <time_frame>180 days</time_frame>
    <description>Evaluate the incidence of adverse events and failures during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor shrinkage ratio, tumor best shrinkage ratio</measure>
    <time_frame>30, 60, 90, 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>30, 60, 90, 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>30, 60, 90, 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival length</measure>
    <time_frame>30, 60, 90, 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response rate for target lesion</measure>
    <time_frame>30, 60, 90, 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free period</measure>
    <time_frame>30, 60, 90, 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period until chronic adverse event</measure>
    <time_frame>30, 60, 90, 180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Malignant Melanoma</condition>
  <condition>Angiosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BNCT(Boron Neutron Capture Therapy)
SPM-011 iv administrates at 200 mg/kg/hr for 2 hours before neutron irradiation. During neutoron irradiation with CICS-1, SPM-011 iv continues at 100mg/kg/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CICS-1 (investigational device),SPM-011(investigational drug)</intervention_name>
    <description>Intravenous administration of SPM-011 and neutron irradiation with CICS-1.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with primary malignant melanoma or angiosarcoma diagnosed histopathologically

          2. Patients with superficial skin lesions whose maximum diameter of the target lesion is
             15 cm or less

          3. Patients with lesions that are lying 6 cm or less from the skin surface to the deepest
             part of the tumor

          4. Patients with lesions in the head, neck, chest, or extremities

          5. Patients who do not have apparent abnormal hematological and biochemical values in the
             latest screening test within 28 days of registration

        Exclusion Criteria:

          1. Patients with obvious disseminated lesions

          2. Patients who have undergone previous treatment of radiation therapy exceeding 75 Gy
             for the target lesion.

          3. Patients with active lesions / active multiple cancers in addition to the target
             lesion

          4. Patients with infections that require systemic treatment.

          5. Patients with active implantable medical devices

          6. Patients with a history of BNCT treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ryo Fujii</last_name>
    <phone>+81-3-3529-6301</phone>
    <email>cics_pv1@cics.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Itami, MD</last_name>
      <phone>+81-3-3542-2511</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BNCT</keyword>
  <keyword>Boron Neutron Capture Therapy</keyword>
  <keyword>Borofalan</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Angiosacronoma</keyword>
  <keyword>skin cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Hemangiosarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

